Daniel J. Clauw, MD; Leila H. Zackrison, MD; Paul Katz, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: Varga and colleagues (1) outline many of the recent advances in our understanding of the eosinophilia myalgia syndrome (EMS). Current theories about the pathogenesis of this disease include direct toxic effects from both eosinophil products and tryptophan metabolites as well as effects mediated by activated T cells, monocytes, and fibroblasts.
Because serum cytokine elevation is known to be related to an activated immune system, we compared the levels of serum cytokines with clinical disease activity in patients with EMS. Sixty-eight serum samples from twenty patients fulfilling the Centers for Disease Control (CDC) criteria for the diagnosis of
Clauw DJ, Zackrison LH, Katz P. Serum Cytokines and the Eosinophilia Myalgia Syndrome. Ann Intern Med. 1992;117:344–345. doi: https://doi.org/10.7326/0003-4819-117-4-344
Download citation file:
Published: Ann Intern Med. 1992;117(4):344-345.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use